姓名

裴之俊

出生年月

1980年11月

单位

湖北医药学院生物医学工程学院/附属太和医院

所属学科

临床医学-影像医学与核医学-核医学，医学技术--影像技术学

职称、职务

教授，主任医师，硕士研究生导师，核医学科主任

E-mail

pzjzml1980@taihehospital.com

联系方式（办公电话）

0719-8801105

研究方向

1.分子影像学的基础研究和临床应用

2.干细胞治疗分子影像无创监测和临床治疗的转化运用

个人简介

一、基本情况

裴之俊，男，1980年11月生，华中科技大学医学影像与核医学博士，主任医师/教授，湖北医药学院硕士研究生导师；十堰市太和医院核医学科主任兼运营管理部主任；湖北医药学院影像医学系副主任；中国核协会核医学委员会委员、中华医学会航海医学会青年委员、湖北省医学会核医学分会副主任委员、十堰市医学会核医学分会主任委员。主要从事分子影像学的基础研究和临床应用、甲状腺核素诊疗等，特别专注于干细胞治疗分子影像无创监测和临床治疗的转化运用。主持国家自然科学基金1项（No.81401447），荣获湖北省科技进步二等奖1项，省级及院级课题多项。在国内外期刊发表论文40余篇，参编1部，第一作者或通讯作者发表SCI论文30余篇，累计影响因子200余分。荣获“湖北省有突出贡献中青年专家”、“湖北省医学青年拔尖人才”、“2015年湖北中青年优秀人才”、“2016年湖北省创新创业好青年”、“太和十大优秀青年”和“太和医院科技精英”等多种称号。

二、代表性项目与成果

1、代表性项目

2、代表性成果

1.Liu Xu Sheng, Zhang Yu, Liu Zi Yue, Gao Yan, Yuan Ling Ling, Zeng Dao Bing, Tan Fan, Wan Hua Bing, Pei Zhi Jun. METTL3 as a novel diagnosis and treatment biomarker and its association with glycolysis, cuproptosis and ceRNA in oesophageal carcinoma[J]. Journal of Cellular and Molecular Medicine, 2024, 28(6): e18195. doi:10.1111/jcmm.18195.

2.Liu Xu Sheng, Liu Zi Yue, Zeng Dao Bing, Hu Jian, Chen Xuan Long, Gu Jiao Long, Gao Yan, Pei Zhi Jun. Functional enrichment analysis reveals the involvement of DARS2 in multiple biological pathways and its potential as a therapeutic target in esophageal carcinoma[J]. Aging-us, 2024, 16(4): 3934-3954. doi:10.18632/aging.205569.

3.Liu Xu Sheng, Chen Yu Xuan, Wan Hua Bing, Wang Ya Lan, Wang Yang Yang, Gao Yan, Wu Li Bing, Pei Zhi Jun. TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association[J]. Scientific Reports, 2024, 14(1): 4042. doi:10.1038/s41598-024-54670-0.

4.Zhang Yao Hua, Liu Xu Sheng, Gao Yan, Yuan Ling Ling, Huang Zhong Min, Zhang Yu, Liu Zi Yue, Yang Yi, Liu Xiao Yu, Ke Chang Bin, Pei Zhi Jun. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters[J]. Lung Cancer, 2024, 188: 107449. doi: 10.1016/j.lungcan.2023.107449.

5.Gao Yan, Chen Yijia, Liu Min, Zeng Daobing, Tan Fan, Wan Huabing, Liu Xusheng, Su Shanchun, Zhang Yaohua, Zhang Yu, Ke Changbin, Pei Zhijun. SLC17A9 as a prognostic biomarker correlated with immune infiltrates in human non-small cell lung cancer[J]. American Journal of Cancer Research, 2023, 13(9): 3963-3982.

6.Liu Xu Sheng, Yuan Ling Ling, Gao Yan, Ming Xing, Zhang Yao Hua, Zhang Yu, Liu Zi Yue, Yang Yi, Pei Zhi Jun. DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma[J]. Journal of Translational Medicine, 2023, 21(1): 574. doi: 10.1186/s12967-023-04454-3.

7.Liu Xu Sheng, Zeng Jing, Zhang Yao Hua, Zhang Yu, Gao Yan, Liu Chao, Pei Zhi Jun. DARS2 is a prognostic biomarker and correlated with immune infiltrates and cuproptosis in lung adenocarcinoma[J]. American Journal of Cancer Research, 2023, 13(3): 818-834.

8.Zhang Yao Hua, Zeng Jing, Liu Xu Sheng, Gao Yan, Kui Xue Yan, Liu Xiao Yu, Zhang Yu, Pei Zhi Jun. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma[J]. Frontiers in Endocrinology, 2022, 13: 1013238. doi: 10.3389/fendo.2022.1013238.

9.Liu Xiao Yu, Gao Yan, Kui Xue Yan, Liu Xu Sheng, Zhang Yao Hua, Zhang Yu, Ke Chang Bin, Pei Zhi Jun. High expression of HNRNPR in ESCA combined with 18F-FDG PET/CT metabolic parameters are novel biomarkers for preoperative diagnosis of ESCA[J]. Journal of Translational Medicine, 2022, 20(1): 450. doi: 10.1186/s12967-022-03665-4.

10.Wu Ruimin, Gao Yan, Zhang Huaqiong, Chen Yijia, Tan Fan, Zeng Daobing, Wan Huabing, Yang Yi, Gu Jiaowei, Pei Zhijun. Metabolic assessment of cerebral palsy with normal clinical MRI using 18F-FDG PET imaging: A preliminary report[J]. Frontiers in Neurology, 2022, 13: 844911. doi: 10.3389/fneur.2022.844911.

11.Liu Xu Sheng, Liu Chao, Zeng Jing, Zeng Dao Bing, Chen Yi Jia, Tan Fan, Gao Yan, Liu Xiao Yu, Zhang Yu, Zhang Yao Hua, Pei Zhi Jun. Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis[J]. Frontiers in Pharmacology, 2022, 13: 1010879. doi: 10.3389/fphar.2022.1010879.

12.Kui Xue Yan, Gao Yan, Liu Xu Sheng, Zeng Jing, Yang Jian Wei, Zhou Lu Meng, Liu Xiao Yu, Zhang Yu, Zhang Yao Hua, Pei Zhi Jun. Comprehensive Analysis of SLC17A9 and Its Prognostic Value in Hepatocellular Carcinoma[J]. Frontiers in Oncology, 2022, 12: 809847. doi: 10.3389/fonc.2022.809847.

13.Gao Yan, Yuan Lingling, Zeng Jing, Li Fuyan, Li Xiaohui, Tan Fan, Liu Xusheng, Wan Huabing, Kui Xueyan, Liu Xiaoyu, Ke Changbin, Pei Zhijun. eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma[J]. Journal of Translational Medicine, 2022, 20(1): 303. doi: 10.1186/s12967-022-03503-7.

14.Liu Xu Sheng, Yang Jian Wei, Zeng Jing, Chen Xue Qin, Gao Yan, Kui Xue Yan, Liu Xiao Yu, Zhang Yu, Zhang Yao Hua, Pei Zhi Jun. SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA[J]. Frontiers in Cell and Developmental Biology, 2022, 10: 853596. doi: 10.3389/fcell.2022.853596.

15.Liu Xu Sheng, Kui Xue Yan, Gao Yan, Chen Xue Qin, Zeng Jing, Liu Xiao Yu, Zhang Yu, Zhang Yao Hua, Pei Zhi Jun. Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma[J]. Frontiers in Genetics, 2022, 13: 835265. doi: 10.3389/fgene.2022.835265.

16.Liu Xu Sheng, Wu Rui Min, Wan Hua Bing, Chen Yi Jia, Tan Fan, Zeng Dao Bing, Yang Yi, Pei Zhi Jun. Situs Inversus Totalis on 18F-FDG PET/CT: A Case Report and a Literature Review[J]. Frontiers in Medicine, 2022, 9: 840795. doi: 10.3389/fmed.2022.840795.

17.Liu Xu Sheng, Liu Jia Min, Chen Yi Jia, Li Fu Yan, Wu Rui Min, Tan Fan, Zeng Dao Bing, Li Wei, Zhou Hong, Gao Yan, Pei Zhi Jun. Comprehensive Analysis of Hexokinase 2 Immune Infiltrates and m6A Related Genes in Human Esophageal Carcinoma[J]. Frontiers in Cell and Developmental Biology, 2021, 9: 715883. doi: 10.3389/fcell.2021.715883.

18.Yang Jian Wei, Yuan Ling Ling, Gao Yan, Liu Xu Sheng, Wang Yu Jiao, Zhou Lu Meng, Kui Xue Yan, Li Xiao Hui, Ke Chang Bin, Pei Zhi Jun. 18F-FDG PET/CT metabolic parameters correlate with EIF2S2 expression status in colorectal cancer[J]. Journal of Cancer, 2021, 12(19): 5838-5847. doi: 10.7150/jca.57926.

19.Liu Xu Sheng, Zhou Lu Meng, Yuan Ling Ling, Gao Yan, Kui Xue Yan, Liu Xiao Yu, Pei Zhi Jun. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis[J]. Frontiers in Immunology, 2021, 12: 724741. doi: 10.3389/fimmu.2021.724741.

20.Liu Xu Sheng, Gao Yan, Wu Li Bing, Wan Hua Bing, Yan Peng, Jin Yang, Guo Shi Bo, Wang Ya Lan, Chen Xue Qin, Zhou Lu Meng, Yang Jian Wei, Kui Xue Yan, Liu Xiao Yu, Pei Zhi Jun. Comprehensive Analysis of GLUT1 Immune Infiltrates and ceRNA Network in Human Esophageal Carcinoma[J]. Frontiers in Oncology, 2021, 11: 665388. doi: 10.3389/fonc.2021.665388.

3、科研获奖

干细胞移植治疗的分子影像无创监测和疗效评估，湖北省科技进步二等奖，湖北省政府，项目第一完成人，2018年

4、学术任职

5、社会荣誉